Publicaciones en colaboración con investigadores/as de Consejo Superior de Investigaciones Científicas (19)

2024

  1. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  3. Phosphatidic Acid Stimulates Lung Cancer Cell Migration through Interaction with the LPA1 Receptor and Subsequent Activation of MAP Kinases and STAT3

    Biomedicines, Vol. 11, Núm. 7

2022

  1. Classification of follicular-patterned thyroid lesions using a minimal set of epigenetic biomarkers

    European journal of endocrinology, Vol. 187, Núm. 3, pp. 335-347

  2. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

    Human Molecular Genetics, Vol. 31, Núm. 23, pp. 3945-3966

  3. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  4. Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries (Nature, (2022), 611, 7934, (115-123), 10.1038/s41586-022-05165-3)

    Nature

  5. Stroke genetics informs drug discovery and risk prediction across ancestries

    Nature, Vol. 611, Núm. 7934, pp. 115-123

2021

  1. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

  2. The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant

    Nature Genetics, Vol. 53, Núm. 10, pp. 1405-1414

2020

  1. Impact of COVID-19 outbreak in reperfusion therapies of acute ischaemic stroke in northwest Spain

    European Journal of Neurology, Vol. 27, Núm. 12, pp. 2491-2498

2019

  1. Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against P. aeruginosa: in vitro and in vivo studies following pulmonary and intramuscular administration

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 18, pp. 101-111

2016

  1. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis

    International Journal of Pharmaceutics, Vol. 498, Núm. 1-2, pp. 263-273

  2. Stability study of sodium colistimethate-loaded lipid nanoparticles

    Journal of Microencapsulation, Vol. 33, Núm. 7, pp. 636-645

2014

  1. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis

    International Journal of Pharmaceutics, Vol. 477, Núm. 1-2, pp. 485-494

2012

  1. Mitochondrial DNA depletion syndrome: New descriptions and the use of citrate synthase as a helpful tool to better characterise the patients

    Molecular Genetics and Metabolism, Vol. 107, Núm. 3, pp. 409-415

2009

  1. Secondary disorders of glycosylation in inborn errors of fructose metabolism

    Journal of Inherited Metabolic Disease, Vol. 32, Núm. SUPPL. 1

2008

  1. Differential splicing, disease and drug targets

    Infectious Disorders - Drug Targets, Vol. 8, Núm. 4, pp. 241-251